Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06211790CT.gov Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | — | Recruiting | — | — | — |
NCT01888042CT.gov Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer | — | Terminated | — | — | — |
NCT01120249CT.gov S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | — | Completed | — | — | — |
NCT00831480CT.gov Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal | — | Terminated | — | — | — |
NCT01217931CT.gov Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial | — | Active Not Recruiting | — | — | — |
NCT01184326CT.gov Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | — | Completed | — | — | — |
NCT01185366CT.gov Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT00392821CT.gov Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer | — | Completed | — | — | — |
NCT00422344CT.gov A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma | — | Completed | — | — | — |
NCT00323739CT.gov Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00331409CT.gov Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | — | Completed | — | — | — |
NCT00303732CT.gov Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | Fudan University | P3 | BB · 64 |
| Alpha-Interferon | Dartmouth-Hitchcock Medical Center | P3 | BBB |
| Girentuximab | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Fluorouracilum | Medical Research Council | P3 | BB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BB |
| Etoposide | City of Hope Medical Center | P3 | BB |
| Lenvatinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Sargramostim | Barbara Ann Karmanos Cancer Institute | P2 | BB |
+42 more in the Kidney Cancer cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Kidney Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-kidney-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →